April 2nd Limit-Up Review: 32 Stocks Hit Limit-Up, Shuanglu Pharmaceutical Achieves 4 Limit-Ups in 7 Days

CryptocurrencySniper · 2026-04-02T08:13:23+00:00

Today, the Shanghai Composite Index fell by 0.74%, the Shenzhen Component Index dropped by 1.6%, and the ChiNext Index declined by 2.31%, with a total trading volume of 1.84 trillion yuan. A total of 32 stocks hit the daily limit, with a limit-up rate of 56.14%. This article is for reference only; investment risks are at your own risk.

CryptocurrencySniper

2026-04-02 08:13:23

Abstract generation in progress

Today, the Shanghai Composite Index (CSI 300) fell 0.74%, the Shenzhen Component Index dropped 1.6%, and the ChiNext Index fell 2.31%. Today’s total market turnover was 1.84 trillion yuan, a decrease of 169.22 billion yuan compared with the previous trading day.

Regarding the number of stocks hitting the daily limit, today there were 32 stocks that closed at the daily limit, and another 25 stocks briefly touched the daily limit during intraday trading; the limit-up success rate was 56.14%.

Disclaimer: This article is generated based on AI and is for reference only and does not constitute any investment advice. Any actions you take are at your own risk. Eastmoney publishes this content to share more information and is not related to the platform’s position. Eastmoney strives to ensure but does not guarantee the completeness and accuracy of the data. If there are any errors or omissions, please refer to the information disclosure media designated by the China Securities Regulatory Commission for listed companies. Eastmoney shall not bear any responsibility for profits or losses arising from all or any part of this material. Users bear the risk of using the service individually, and Eastmoney does not provide any form of guarantee.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.